Renalytix Plc RNLX
At closeOct 7, 2024, 4:00 PM EDT
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 22.55M
- Revenue (ttm)
- 2.29M
- EPS (ttm)
- -0.62
- Shares out
- 82.96M
- P/E ratio
- -0.33
- Forward P/E
- -1.09
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 726.33K
- Avg volume
- 714.54K
- Open
- 0.2098
- Previous close
- 0.2071
- Day's range
- 0.19 – 0.225
- 52-week range
- 0.12 – 2.40
- Beta
- 2.10
- Analysts
- Strong Buy
- Price target
- 2.50 (+1107.1%)
- Earnings date
- Nov 12, 2024
2Y -1.2798 (-89.50%)
Key statistics
- Enterprise value
- 30.40M
- PEG ratio
- 0.00
- Price / sales
- 9.85
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 13.10%
- Free cash flow
- -19.47M
- Total cash
- 4.68M
- Total debt
- 8.54M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 0.269472
- 200-day average
- 0.510152
Analyst view
Consensus: strong buy
- Target (low)
- 2.00
- Target (mean)
- 2.50
- Target (high)
- 3.00
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Next earnings
Nov 12, 2024
Expected Nov 12, 2024. Consensus EPS estimate -0.05.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| May 15, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Feb 14, 2024 | Dec 1, 2023 | -0.09 | — | — | — |
| Nov 14, 2023 | Sep 1, 2023 | -0.11 | — | — | — |
| Sep 28, 2023 | Jun 1, 2023 | -0.13 | — | — | — |
| Jun 9, 2023 | Mar 1, 2023 | -0.13 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jun 29, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 11, 2023 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 4, 2023 | HC Wainwright & Co. | reit | — | Buy |
| Apr 2, 2023 | HC Wainwright & Co. | main | — | Buy |
| Apr 2, 2023 | BTIG | main | — | Buy |
| Dec 1, 2022 | HC Wainwright & Co. | main | — | Buy |
About Renalytix Plc
Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix Plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; and Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Health Information Services
- Country
- United States
- Website
- renalytix.com
News
Renalytix Plc (RNLXY) Shareholder/Analyst Call Transcript 
Renalytix rises 7% as UBS holding grows and CEO buys shares 
Renalytix shares surge 19% as trading resumes after cash call 
Renalytix shares climb 24% as two-year kidney study data published 
Renalytix™ and Carna Health Partner to Solve Kidney Disease Crisis: Bridging the Existing Gap Between Population Screening and Precision Intervention 
Renalytix first half revenues rise, but cautions pipeline is taking longer to convert 
Renalytix shares fall 25% as revenues miss expectations 
Renalytix expands US footprint with three new clinical partnerships 
Renalytix (LON:RENX) Trading Down 1.7% – What’s Next? 
Renalytix reports £4m balance sheet boost as notes convert
Your note
Sign in to keep a note on RNLX — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Gilder, Gagnon, Howe & Co. | 2.16% | 1,027,746 | 3.00M | Jun 29, 2023 |
| Pinnacle Associates, Ltd. | 1.77% | 839,322 | 2.45M | Jun 29, 2023 |
| Pentwater Capital Management Lp | 1.19% | 565,000 | 1.65M | Jun 29, 2023 |
| Tejara Capital Ltd | 0.93% | 441,805 | 1.29M | Jun 29, 2023 |
| Corient Private Wealth LLC | 0.47% | 225,724 | 659.11K | Jun 29, 2023 |
| Lazard Asset Management LLC | 0.30% | 143,930 | 420.27K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| USAA Mutual Fund Tr-Small Cap Stock Fund | 0.03% | 13,296 | 38.56K | Jul 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.01% | 4,865 | 11.82K | May 30, 2023 |